Zanubrutinib (BGB-3111), a next-generation BTK inhibitor with minimal off-target effects, has demonstrated higher efficacy and safety for treating Waldenström macroglobulinemia, compared with ibrutinib (7). This evidence concerns the gene BTK and Waldenstrom macroglobulinemia.